Cubist Pharmaceuticals, Inc. (CBST) and Hydra Biosciences, Inc. Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain
1/10/2012 6:26:37 AM
More...
|
Hydra Biosciences, Inc. and Cubist Pharmaceuticals, Inc. (CBST) Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
10/19/2009 8:43:13 AM
More...
|
Research published in PNAS by Hydra Biosciences, Inc. is First Demonstration in Mammals that TRP Ion Channel Drug Can Treat Allergy-Induced Asthma
5/19/2009 10:00:12 AM
More...
|
Hydra Biosciences, Inc. Raises $22 Million in Series D Financing
1/16/2009 6:46:30 AM
More...
|
Hydra Biosciences, Inc. Bolsters Discovery and IP Capabilities with Key Additions to Executive Management Team
10/24/2008 8:43:45 AM
More...
|
Hydra Biosciences, Inc. Raises $34M in Venture Capital
3/14/2008 12:15:34 PM
More...
|
Hydra Biosciences, Inc. Announces Data Revealing the Crucial Role Played by the TRPA1 Ion Channel in a Standard Model of Pain Receptor Activation
8/7/2007 1:27:20 PM
More...
|
Hydra Biosciences, Inc. Appoints Russell H. Herndon As Chief Executive Officer
1/5/2006 2:28:09 PM
More...
|
Weber Shandwick Worldwide Release: Biotechnology And Pharmaceutical Executives From New England's Top Companies To Attend The Second Annual Convergence - The Life Sciences Leaders Forum
10/19/2005 5:13:16 PM
More...
|
Hydra Biosciences, Inc. To Present At Convergence 2005: The Drug/Device Summit, March 21-23, 2005
10/19/2005 5:12:51 PM
More...
|
|